摘要
肠杆菌科细菌是医院感染的主要病原菌,碳青霉烯类抗菌药物是治疗肠杆菌科细菌感染的主要药物。近年随着抗菌药物的广泛应用和(或)不合理使用,碳青霉烯类耐药肠杆菌科细菌(carbapenem-resistant Enterobacteriaceae,CRE)的检出率也日益增多。CRE所致感染可选药物极为有限,有时甚至面临"无药可选"的境地。本文将从CRE耐药机制、对CRE感染可能有效的抗菌药物、联合治疗方案的选择及新型药物研发等方面进行介绍,以促进CRE感染治疗的合理用药。
Enterobacteriaceae bacteria are the main pathogens of nosocomial infection. Carbapenem antibiotics are the main drugs to treat Enterobacteriaceae bacterial infections. In recent years, because of the widely and （or） irrational use of antimicrobial agents, the detection rate of carbapenem-resistant Enterobacteriaceae （CRE） is increasing. The drugs that can be used to treat CRE infections are extremely limited, sometimes we have no drug to use. To promote the rational use of the antibiotic drugs of CRE infections, this paper will introduce the resistant mechanism of CRE, the main therapy drugs of CRE infections, combination therapy options and new drug development.
出处
《中国医学前沿杂志（电子版）》
2017年第4期6-9,共4页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
基金
国家科技支撑计划(2012EP001004)
